**Abstract**

**Objective:** A post-hoc subgroup analysis was pemathewsMrformed to compare outcomes following administration of paliperidone palmitate 3-monthly (PP3M) versus 1-monthly (PP1M) injectable in patients with schizophrenia previously treated/not treated with oral risperidone/paliperidone (RIS/PALI) before study entry.

**Methods:** Patients received PP1M (50, 75, 100, or 150 mg eq.) during 17-week open-label (OL) phase, randomized (1:1) to PP3M (175, 263, 350, or 525 mg eq.) or PP1M (50, 75, 100, or 150 mg eq.) during 48-week double-blind (DB) phase. Based on prior RIS/PALI exposure, outcomes were compared between two subgroups: recent=at least 28 days of RIS/PALI exposure with last dose within 14 days before study entry; no=no RIS/PALI exposure within 60 days before study entry.

**Results:** 452 patients had received recent RIS/PALI (n=323 \[71%\] randomized to PP3M=166; PP1M=157), and 709 did not receive RIS/PALI (n=506 \[71%\] randomized to PP3M=254; PP1M=252). Improvements in PANSS scores following OL PP1M were similar in recent RIS/PALI (mean \[SD\] of -18.3 \[17.96\]) and no prior RIS/PALI (-21.1 \[16.40\]) subgroups at OL endpoint. Relapse-free rates during DB phase were comparable across recent RIS/PALI (PP3M: 89.7%; PP1M: 87.1%, 95% CI for difference: \[-4.7; 10.0\]) and no RIS/PALI subgroups (PP3M: 91.6%; PP1M: 90.8%, 95% CI for difference: \[-4.5; 6.0\]). Incidences of extrapyramidal symptom-related adverse events were: recent RIS/PALI (OL PP1M:12.4%; DB: PP3M:7.8% vs PP1M:7.0%) and no RIS/PALI (OL PP1M: 11.4%; DB: PP3M: 7.1% vs PP1M: 6.7%).

**Conclusion**: This exploratory analysis suggests comparable treatment outcomes and tolerability following PP3M or PP1M administration in patients with schizophrenia, irrespective of prior treatment with/without oral RIS/PALI.
